Your session is about to expire
← Back to Search
XPro1595 for Alzheimer's Disease
Study Summary
This trial will assess if a drug called XPro1595 can improve cognition, functioning & brain quality in people with Alzheimer's.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My medications for mild cognitive impairment or Alzheimer's disease will stay the same during this study.I can follow the study's procedures and assessments.I don't have any health issues that could affect my safety in the study.I am willing and able to agree to participate in the study, or my legal representative can consent for me.I will use effective birth control during and for 90 days after treatment.
- Group 1: Experimental: 1.0 mg/kg XPro1595
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What type of participants are most suitable for this research endeavor?
"This study seeks to enrol 261 individuals with neurodegenerative diseases who are aged between 55 and 86."
Is this experimentation currently enrolling volunteers?
"According to information hosted on clinicaltrials.gov, this trial is currently in the process of recruiting patients and was first published February 21st 2023 with a recent update recorded on August 23rd 2023."
Is enrollment open to those over 45 years of age in this medical experiment?
"Applicants between the ages of 55 and 86 may participate in this study. In comparison, there are 224 trials associated with individuals under 18 years old and 1196 studies for those over 65."
Can you provide a count of the Canadian medical facilities administering this clinical investigation?
"At the present time, there are 5 trial sites recruiting patients. Conveniently located in Ivanhoe, Perth and Toronto as well as an additional 5 locations; it is encouraged that participants choose a site close to them to reduce travel strain."
Has the U.S. Food and Drug Administration sanctioned the 1.0 mg/kg dosage of XPro1595?
"Our evaluative team at Power has given Experimental: 1.0 mg/kg XPro1595 a safety rating of 2 as there is some evidence confirming its safety, but none backing up its efficacy due to this being a Phase 2 trial."
What is the cap on participant numbers for this trial?
"Affirmative, the public information hosted on clinicaltrials.gov notes that enrolment for this medical study is ongoing. This trial was initially posted to be conducted in February 2021 and has been recently updated as of August 2023. 261 participants are needed between 5 different sites."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger